Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | RPA1 | P27694 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5698586 | 0.86 | PTGS2 (0.67) | PTGS2PTGS1RPA1SMN1; SMN2MEN1 | |
| SCHEMBL8286994 | 0.86 | PTGS2 (0.71) | PTGS2PTGS1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL27584983 | 0.86 | PTGS2 (0.67) | PTGS2PTGS1RPA1SMN1; SMN2MEN1 | |
| SCHEMBL212658 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1ALDH1A1PDPK1 | |
| SCHEMBL6339240 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1ALDH1A1PDPK1 | |
| SCHEMBL5698729 | 0.83 | PTGS2 (0.67) | PTGS2PTGS1ALDH1A1RPA1SMN1; SMN2 | |
| SCHEMBL8290876 | 0.83 | PTGS2 (0.73) | PTGS2PTGS1ALDH1A1 | |
| SCHEMBL9206762 | 0.83 | PTGS2 (0.54) | PTGS2PTGS1ALDH1A1 | |
| Sulfamide SCHEMBL7159984 | 0.82 | PTGS2 (0.76) | PTGS2PTGS1ALDH1A1MEN1KMT2A | |
| SCHEMBL8635509 | 0.81 | PTGS2 (0.78) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005046615-A2 | COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM MEDIATED DISORDERS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005018563-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A PHOSPHODIESTERASE INHIBITOR FOR THE TREATMENT OF ISCHEMIC MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018541-A2 | COX-2 INHIBITOR AND SEROTONIN MODULATOR FOR TREATING CNS DAMAGE | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005009354-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN IKK INHIBITOR FOR THE TREATMENT OF ISCHEMIC-MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | disclosed |